To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes
Phase 3
- Conditions
- Type 2 Diabetes
- Registration Number
- JPRN-jRCT2080220294
- Lead Sponsor
- ovartis Pharma K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 370
Inclusion Criteria
Ages Eligible for Study: 20 Years and above, Genders Eligible for Study: Both
Inclusion Criteria:
- Diagnosis of type 2 diabetes
- Patients who have been placed on diet and exercise therapy without achieving target blood glucose levels
- Outpatients
Exclusion Criteria
- Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes
- Significant heart diseases
- Significant diabetic complications
Other protocol-defined inclusion/exclusion criteria may apply
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary Outcomes: Change in HbA1c after 12 weeks Secondary Outcomes: Change in FPG after 12 weeks; Change in Fasting Lipids after 12 weeks; Change in HOMA-IR after 12 weeks; Change in HOMA-B after 12 weeks; Safety Profile after 12 weeks treatment
- Secondary Outcome Measures
Name Time Method